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From the Editor 
 
Hepatitis C: A Stakeholder Analysis 
__________________________________________ 
 
Imagine the following clinical scenario. A robust 45-year old female executive goes 
to her family doctor for an annual screening physical exam. She has been well her 
entire life and has been responsible for coordinating the health care of her husband 
and their adolescent children. Several days after her primary care doctor visit, she 
receives a telephone call alerting her to the fact that her liver enzymes (the test 
used to gauge liver function) are slightly elevated.1 After an additional follow-up 
visit, she is diagnosed with a chronic viral infection of her liver that could slowly 
destroy this vital organ and, indeed, kill her in the next decade. This is the clinical 
face of infection with the hepatitis-C virus (HCV). 
 
HCV is now the most common cause of viral-related cirrhosis in the United States 
and is currently the leading indication for liver transplantation. Nearly four million 
Americans, about 2% of the adult population, are infected with the hepatitis-C virus 
– most of them without knowing it. The numbers are undeniable. Nine thousand 
people die each year in the U. S. from complications of HCV (a number that is 
expected to triple by 2010).2 Once infected, only 15% of patients are able to clear 
the virus. The other 85% suffer chronic infection3; of these, about 20% will suffer 
from progressive liver disease. 
 
Where did this silent killer come from, and is any effective therapy currently 
available? Clinicians know that diagnosis of infection with different hepatitis viruses 
has been an important part of primary care practice for decades. Dr. Baruch 
Blumberg received the Nobel Prize for identifying the hepatitis-B virus in the mid 
1960s, which paved the way for researchers to develop reliable blood tests for the 
virus. When new tests for hepatitis-A and B became available in the 1970s, 
researchers soon found that a substantial portion of cases of post-transfusion 
hepatitis were caused by neither of these two viruses.2 This was labeled so-called 
non-A non-B hepatitis. It took another 15 years for researchers to identify many of 
these cases as hepatitis-C related.   
 
Risk factors for hepatitis-C virus infection3 include intravenous drug use (even if only 
once), transfusion of blood or blood products before 1992, intranasal cocaine use, 
history of multiple sexual partners, hemodialysis, needle stick injuries, history of 
sexually transmitted diseases, extensive body piercing, tattoos, and a history of 
having been in prison; resulting in tens of millions of Americans who are at risk.   
 
While this is not the appropriate setting to evaluate all of the clinical trials for the 
therapy of HCV, it is appropriate to summarize the current treatment options as 
follows. After clinical evaluation, which may include a liver biopsy and an assessment 
of viral load, clinicians can offer patients therapy, which may include interferon alfa 
2b alone or in combination with ribavirin.3 When used at the recommended dosages, 
interferon alfa normalizes liver enzyme levels in 40 to 50% of patients and HCV 
becomes undetectable in 30 to 40% of patients during treatment. Yet, overall, only 
10 to 15% of patients treated achieve long-term viral eradication.4 Combination of 
interferon plus ribavirin increases long term eradication to 35-40% only. 
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Certainly, many important clinical challenges remain about the most effective 
therapy for HCV infection. I would like now to turn to a stakeholder analysis and 
review the impact of this silent epidemic on providers, patients, payers, and 
employers. This stakeholder analysis will focus on the future challenge for successful 
HCV therapy from each of the unique perspectives. 
 
For providers, the key clinical mission may be to eradicate HCV in all patients for 
whom it is possible to do so and to stem the progression of liver disease.5 As always, 
providers should seek to maximize the underlying health status of the individuals , 
prevent disability wherever possible, and maintain a reasonable quality of life. All of 
this must be done, of course, within the context of minimizing cost to the health care 
system. Collectively, it is a formidable challenge for the provider stakeholders. 
 
In addition, from the provider perspective, we need to implement wide-spread 
physician education programs to help providers recognize the risk factors for HCV 
infection, to specifically motivate them to ask their patients about these risk factors, 
and to design appropriate referral tools to help primary care providers send select 
patients on to subspecialists for definitive care. Our collective track record as 
providers in implementing best practices and coordinating care across multiple 
caregivers could certainly be improved. HCV presents a “double whammy” to 
providers in terms of the complexities of disease screening and the uneven evidence 
about disease treatment.5
A case-in-point is, for providers who graduated from medical school as late as 1981, 
this disease was never taught in the classroom!   
 
For patients, HCV presents comparable sociologic and economic challenges. What are 
the best methods for educating those patients who have tested positive for HCV?  If 
one believes that the patient’s role in the doctor-patient relationship is changing, 
especially with the advent of medical consumerism, how then can we take advantage 
of some of the new tools and techniques to engage patients in their own care? Once 
patients are diagnosed with HCV, how can we work together to improve their access 
to care and determine where a patient may be relative to their “readiness to change” 
index? What can we learn from studies demonstrating low patient compliance with 
the therapy for other chronic illnesses such as hypertension and hyperlipidemia?  All 
levels of the industry must encourage patient adherence to appropriate therapeutic 
regimens.   
 
Because HCV affects nearly 2% of the U.S. population, all payers should be 
concerned about reducing future expenses.  No managed care organization can 
escape the burden of HCV!  As a result, these stakeholders need to harness the tools 
of disease management and demand management to assess a population at risk for 
HCV and to deliver targeted services for them. Once patients are identified, new 
technologies linked to case management programs may be called for.  Perhaps 
payers can facilitate appropriate physician network development to handle the 
“connections” needed among primary care doctors, patients, and subspecialists. How 
can we help to hold payers responsible and accountable for their care of persons with 
HCV? What rate-based measures of quality might apply to this population such as 
percentage of eligible patients who were successfully screened, or who completed a 
particular therapeutic regimen? Given the rapid turnover of patients enrolled in any 
single managed care plan and the uneven economic incentives to practice primary 
prevention; no single payer can be held responsible for society’s obligation to treat 
HCV. In short, the public health dimensions of the HCV challenge transcend all 
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payers. In our diversified health care economy, this could be a particularly vexing 
problem in the near future. 
 
HCV infection has a major impact on employers, the last of our four stakeholders. 
Some analysts believe that HCV contributes to an 8% drop in productivity in a typical 
work month in the United States due to absenteeism and related causes6.
Employers, after all, bear much of the economic risk for both the direct and indirect 
costs of disability for persons infected with HCV. In certain job categories, especially 
many of those in the health care sector, employees are at a higher risk exposure 
level to get HCV in the first place.  Employers will need to seek out innovative 
pharmaceutical coverage programs for those stricken with HCV. They will need to 
design worker’s compensation plans appropriate to the risk that their employees may 
face both on and off the job site. Employers will have to interpret performance 
information provided by managed care plans for example, and share this with their 
employees. Perhaps one could envision a day when a particular plan’s performance 
with regard to the care and therapy of persons with HCV far exceeds another plan, 
resulting in a shift of employees from one plan to another stimulated by data 
provided by the employer itself. Maybe employers should be actively involved in 
efforts to educate employees about HCV and to provide confidential screening at the 
workplace.6
HCV infection is a major public health problem affecting all the stakeholders in our 
system. No one can hide. What is your organization doing about this challenge? As 
always, I am interested in your views and you can contact me at 
david.nash@mail.tju.edu.
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Postscript: The Centers for Disease Control (CDC) posted on its World-Wide Web 
site an interactive web-based training program titled: “Hepatits C: What Clinicians 
and Other Health Professionals Need to Know.” The Program is at 
http://www.cdc.gov/hepatitis.
This program provides users with up-to-date information on the epidemiology, 
diagnosis, and management of hepatitis C virus (HCV) infection and HCV-related 
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chronic disease. Users also can test their knowledge of the material through study 
questions at the end of each section and case studies at the end of the program. 
Continuing medical and nursing education credits are available free from the CDC on 
completion of the training. The American Academy of Family Physicians also will 
grant the academy’s education credits on completion of training and filing with the 
academy. 
 
